Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Our hypothesis is that ex vivo activated immune cells would produce multiple known and unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell growth and differentiation. Additionally, these cells travel and home to bone marrow as well as spleen and liver involved in hematopoietic activities, where direct cell-cell contact may be beneficial.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
• Collaborators: Liu Hua Qiao Hospital; The 12th Guangzhou Municipal Hospital
• Treatments: Immunologic Factors

Criteria

Inclusion Criteria:

• Clinical Diagnosis of Idiopathic Aplastic Anemia

• Not Eligible for Bone Marrow Transplantation

• Not Responsive to Conventional Immunosuppressive Therapy

Exclusion Criteria:

• Leukemia or MDS or PNH or Fanconi's Disease

• pregnancy

• Allergic to Blood Product

• Severe Hypertension or Heart Disease

• Liver or Kidney Disease